Harvard Bioscience Announces Appointment of Stephen DeNelsky to Board of Directors

Core Insights - Harvard Bioscience, Inc. has appointed Stephen DeNelsky to its Board of Directors, effective September 5, 2025, enhancing its governance and strategic direction [1][2]. Company Overview - Harvard Bioscience is a leading developer, manufacturer, and seller of technologies and services that advance life science applications, including research, drug discovery, and preclinical testing [5]. Board Member Profile - Stephen DeNelsky brings 30 years of experience in healthcare equity research and analysis, currently serving as Managing Director at Oaktree Capital Management, with prior roles at Marathon Asset Management and Life Sciences Alternative Funding [3]. - DeNelsky has extensive board experience, currently serving on the board of Visioncare Inc and previously on the boards of Integrated Diagnostics and AMICAS, Inc [3]. Leadership Comments - John Duke, President & CEO, emphasized the importance of DeNelsky's financial strategy expertise for the company's future [2]. - Katherine Eade, Lead Independent Director, noted the immediate benefits of DeNelsky's life sciences lending expertise [4].